openPR Logo
Press release

Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer

Sacituzumab Govitecan Approval for Advanced or Metastatic

On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.

Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including metastatic triple-negative breast cancer (TNBC) and metastatic urothelial cancer, where high expression is associated with poor survival and relapse.

The drug was created by site-specifically conjugating a TROP-2-targeting antibody with a drug to antibody ratio of 7.6 (which is about twice that of other antibody-drug conjugates) of the moderately toxic drug, SN-38, the active metabolite of irinotecan, using a pH-sensitive linker.

Bladder cancer
Urothelial cancer is the most common type of bladder cancer and occurs when the urothelial cells that line the inside of the bladder and other parts of the urinary tract grow unusually or uncontrollably. 

Earlier this year, the American Cancer Society published the annual Facts and Figures report which showed while the organization expects a decline in some cancers, cases of bladder cancer are expected to increase in 2021.

According to the American Cancer Society, an estimated 83,720 people in the United States will be diagnosed with bladder cancer in 2021, and almost 90% of those diagnoses will be Urothelial cancer. The data shows an increase of approximately 3% compared to the prior year. That means that on average, 228 people will hear the devastating words, “You have bladder cancer,” each day this year.  Furthermore, an estimated 17,000 patients will not survive the disease and there are thought to be more than 600,000 people living with bladder cancer in the United States, more than the population of the state of Wyoming.

“[Altough] we celebrate the decline in certain cancer types as well as the progress against them,” said Andrea Maddox-Smith, Chief Executive Officer of the Bladder Cancer Advocacy Network (BCAN).

“The American Cancer Society’s report is a stark reminder that while bladder cancer is still one of the most commonly diagnosed cancers in the United States, rising expected case numbers in 2021 speaks to the urgent need for more and better treatments and expanded assistance for bladder cancer patients,” she added.

The relative five-year survival rate for patients with metastatic urothelial cancer is 5.5%.

“Cases of urothelial cancer continue to rise in the U.S., yet prognosis remains the same for the vast majority of patients,” Maddox-Smith said
“Bladder cancer patients need as many treatment options as possible, and we are pleased that Sacituzumab Govitecan can be a potentially viable treatment for them,” she concluded.

Treatment options
“Only a fraction of patients derive long-term benefit from previously approved cytotoxic therapy or immunotherapy, leaving a great unmet need for treatment options for patients with advanced urothelial cancer who have progressed on first- and second-line therapies,” said Scott T. Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, an oncologist at New York-Presbyterian/Weill Cornell Medical Center and principal investigator of the TROPHY study and a paid consultant for Gilead Sciences.

“The response rate and tolerability seen with Sacituzumab Govitecan may provide physicians an effective new treatment option for patients whose cancer continues to progress even after multiple therapies,” Tagawa added.

Biochempeg is a leading worldwide PEG & ADC linkers supplier that dedicated to manufacturing and supplying a variety of high purity PEG linkers, ADC linkers and other click chemistry reagents to empower ADC drug research & development. Product 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid is a fragment of Sacituzumab govitecan(IMMU-132), we have this product in stock, we can also support custom synthesis with different quantities based on customers' requirment.

Biochempeg Scientific Inc.
108 Water Street, Room 4D, Watertown, MA 02472, USA
TEL: 1-857-366-6766
Fax: 617-206-9595
Email: sales@biochempeg.com
Website: https://www.biochempeg.com

Biochempeg provides high purity PEG derivatives and reagents, monodisperse PEG, Click Chemistry reagents, PEGylation services and custom PEG derivative synthesis to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer here

News-ID: 2277899 • Views: 370

More Releases from Biochempeg Scientific Inc.

Semaglutide VS Liraglutide: Which Is Better For Weight Loss
Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide, according to a study published in the Jan. 11 issue of the Journal of the American Medical Association. Domenica M. Rubino, M.D., from the Washington Center for Weight Management and Research in Arlington, Virginia, and colleagues compared the efficacy and adverse event
What Are Components And Mechanism Action of Antibody-Drug Conjugates
Antibody-Drug Conjugates (ADC) is a type of anticancer drug that links a drug to cancer-targeting antibodies. The antibody detects tumor-specific proteins expressed on cancer cells and directs the cytotoxic anticancer drug towards the cancer cell. Compared to alternative cancer treatments, for example, chemotherapy, immunotherapy, radiation, and stem cell therapy, ADC combines chemotherapy and immunotherapy and allows selective delivery of anticancer drugs and reduces systemic exposure and toxicity of anticancer drugs. Components of ADC One
Sacituzumab govitecan shows promise in treating the most aggressive type of brea …
A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a targeted antibody, has been found in a global phase 3 clinical study to nearly double the survival time of patients with refractory metastatic triple-negative breast cancer. The study of the ADC drug sacituzumab govitecan (SG), for which Massachusetts General Hospital (MGH) was a lead clinical research site after serving as
ADC Has Curative Effect On Cell Surface Protein In Neuroblastoma
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells. The researchers published their findings today in Science Translational Medicine. In 2008, researchers discovered mutations in the anaplastic lymphoma kinase (ALK) gene as the major cause of the inherited form of neuroblastoma and showed that these same mutations

All 5 Releases


More Releases for Sacituzumab

Sacituzumab Govitecan, A Kind of ADC Drug Against Triple-Negative Breast Cancer
On April 22, the FDA approved sacituzumab govitecan for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. It is a next generation antibody-drug conjugate designed by Immunomedics Inc. Sacituzumab govitecan is the first antibody-drug conjugate approved by the FDA specifically for relapsed or refractory metastatic triple-negative metastatic breast cancer. It is also the first FDA-approved anti–Trop-2 antibody-drug conjugate.
US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025
"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights: US Breast Cancer Drug Market Opportunity: US$ 20 Billion US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment US Breast Cancer Marketed Drugs: 42 Drugs US Breast Cancer Drug Clinical Pipeline: 317 Drugs Dosage and Pricing Insight for Preventive and Treatment Drugs US Breast Cancer Drug Market Dynamics For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report:
Triple-Negative Breast Cancer Treatment Market: Global Drivers, Restraints, Oppo …
Breast cancer is cancer that effects the breast tissue. Breast cancer is the most commonly diagnosed cancer among American women, besides skin cancer. Currently, to treat breast cancer various drugs like hormonal treatment, HER2 receptor-based drugs are available in the market. However, these drugs will not act against on triple-negative breast cancers this is mainly due to absence of receptors in triple-negative breast cancer conditions. Usually, in breast cancer cells
Triple-Negative Breast Cancer Treatment Market Set to Witness an Uptick During 2 …
Breast cancer is cancer that effects the breast tissue. Breast cancer is the most commonly diagnosed cancer among American women, besides skin cancer. Currently, to treat breast cancer various drugs like hormonal treatment, HER2 receptor-based drugs are available in the market. However, these drugs will not act against on triple-negative breast cancers this is mainly due to absence of receptors in triple-negative breast cancer conditions. Usually, in breast cancer cells
Current And Future Market Analysis Of Small Cell Lung Cancer (SCLC) Market 2024: …
"The Latest Research Report OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Small Cell Lung Cancer Market Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Fo …
Researchmoz added Most up-to-date research on "OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024" to its huge collection of research reports. Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung